Rhythm Express has launched RX-1 Sleep, an FDA-cleared system that helps healthcare professionals evaluate sleep-related breathing disorders in adults suspected of having sleep apnea. The system expands the company’s remote cardiac monitoring platform by allowing sleep-disordered breathing and cardiac rhythm to be evaluated during the same monitoring period.
About RX-1 Sleep
RX-1 Sleep is prescription-use software that analyzes data from the FDA-cleared RX-1 mini cardiac monitor and a compatible Viatom pulse oximeter. The system provides sleep-related measurements, including apnea-hypopnea index, sleep/wake status, respiratory effort, and body position, while incorporating overnight oxygen saturation information.
When sleep and cardiac monitoring are prescribed together, patients can complete up to three nights of sleep assessment while undergoing cardiac monitoring for up to 30 days. The RX-1 mini provides electrocardiogram and heart rhythm data that can aid clinicians in evaluating arrhythmia activity, including atrial fibrillation burden. The connected platform brings cardiac, oxygen saturation, activity, and sleep-related information together for healthcare professional review.
During the sleep assessment, patients wear the RX-1 mini and a compatible finger pulse oximeter. Recorded information is sent to Rhythm Express monitoring centers, where specialized technicians prepare cardiac and sleep summary reports for healthcare professionals. The results are intended to aid clinicians in their evaluation and diagnosis.
RX-1 Sleep received FDA 510(k) clearance (K253148) to aid in evaluating sleep-related breathing disorders in adults suspected of having sleep apnea.
About home sleep apnea tests
Home sleep apnea tests (HSATs) collect breathing, blood oxygen, and, depending on the device, other physiological data to help diagnose sleep apnea in appropriate patients. An in-lab sleep study may be needed when HSAT results are negative or inconclusive.
Read more industry news from the AASM.
